[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100635061":3},{"organization":4,"outcomesModule":7,"designInfo":14,"detailedDescription":13,"studyPopulation":17,"armGroups":13,"interventions":13,"overallOfficials":18,"centralContacts":25,"locations":33,"responsibleParty":51,"collaborators":13,"id":53,"slug":13,"hasResults":54,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":13,"eligibilityCriteria":58,"healthyVolunteers":54,"sex":59,"minAge":13,"maxAge":13,"enrollmentInfo":60,"targetDuration":63,"studyType":64,"phases":13,"briefSummary":65,"conditions":66,"keywords":13,"overallStatus":36,"whyStopped":13,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":77},{"fullName":5,"class":6},"Akeso","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":13},[9],{"measure":10,"description":11,"timeFrame":12},"Overall Survival (OS)","OS is defined as the time from randomization to death due to any cause.","Up to approximately 5 years",null,{"allocation":13,"interventionModel":13,"interventionModelDescription":13,"primaryPurpose":13,"observationalModel":15,"timePerspective":16,"maskingInfo":13},"COHORT","PROSPECTIVE","Subjects are enrolled from participants who previously took part in the sponsor-initiated clinical trials of cadonilimab (AK104).",[19,23],{"name":20,"affiliation":21,"role":22},"Jiafu Ji, MD","Peking University Cancer Hospital & Institute","PRINCIPAL_INVESTIGATOR",{"name":24,"affiliation":21,"role":22},"Lin Shen, MD",[26,31],{"name":27,"role":28,"phone":29,"phoneExt":13,"email":30},"Zhifang Yao，MD","CONTACT","86-0760-89873999","clinicaltrials@akesobio.com",{"name":20,"role":28,"phone":13,"phoneExt":13,"email":32},"jijiafu@hsc.pku.edu.cn",[34],{"facility":35,"status":36,"city":37,"state":13,"zip":13,"country":38,"countryCode":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":46},"Peking University Cancer Hospital","RECRUITING","Beijing","China","CN",{"type":41,"coordinates":42},"Point",[43,44],116.39723,39.9075,{"lat":44,"lon":43},[47,49],{"name":48,"role":28,"phone":13,"phoneExt":13,"email":32},"Jiafu Ji, MD, Principal Investigator",{"name":50,"role":28,"phone":13,"phoneExt":13,"email":13},"Lin Shen, MD, Principal Investigator",{"type":52,"investigatorFullName":13,"investigatorTitle":13,"investigatorAffiliation":13,"oldNameTitle":13,"oldOrganization":13},"SPONSOR","100635061",false,"NCT07547787","A Long-term Follow-up Study of Subjects Enrolled in Clinical Trials of Cadonilimab (AK104)","An Extension Study for Collecting Long-term Follow-up Data of Subjects Enrolled in Clinical Trials of Cadonilimab (AK104)","Inclusion Criteria:\n\n1. Ability to understand and voluntarily sign a written informed consent form (ICF), which must be signed before the specified study procedures required for the study are performed.\n2. Subjects have received prior systemic therapy in sponsor-initiated clinical trials of cadonilimab (AK104), and this extension study is conducted after the completion of the original trial.\n3. Agree to proceed with the extended follow-up procedures.\n4. This is an observational and non-interventional clinical study, in which subjects are allowed to participate in other clinical studies at the same time.\n\nExclusion Criteria:\n\n* None","ALL",{"count":61,"type":62},610,"ESTIMATED","5 Years","OBSERVATIONAL","This is an observational and non-interventional clinical study that only collects long-term follow-up data of the subjects. As the world's first approved PD-1\u002FCTLA-4 bispecific antibody for marketing, Cadonilimab may confer long-term survival benefits.",[67],"Locally Advanced Unresectable or Metastatic Gastric Cancer","2026-04-17",{"date":70,"type":71},"2026-04-23","ACTUAL",{"date":73,"type":71},"2024-12-26",{"date":75,"type":62},"2040-12-31",{"name":5,"class":6},1]